(Q35733486)

10 August 2017

1 reference

title

Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives (English)

1 reference

10 August 2017

1 reference

Jean-Louis Beaudeux

1

1 reference

10 August 2017

Philippe Giral

2

1 reference

10 August 2017

Eric Bruckert

3

1 reference

10 August 2017

Marie-José Foglietti

4

1 reference

10 August 2017

M John Chapman

5

1 reference

10 August 2017

publication date

1 February 2004

1 reference

Clinical Chemistry and Laboratory Medicine

10 August 2017

published in

1 reference

10 August 2017

volume

42

1 reference

10 August 2017

issue

2

1 reference

10 August 2017

page(s)

121-131

1 reference

Selective matrix metalloproteinase (MMP) inhibition in rheumatoid arthritis--targetting gelatinase A activation

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Targeted disruption of the matrix metalloproteinase-9 gene impairs smooth muscle cell migration and geometrical arterial remodeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

ApoE knockout mice expressing human matrix metalloproteinase-1 in macrophages have less advanced atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Matrix metalloproteinases A review of their structure and role in acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The Care Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Matrix metalloproteinase disruption of the extracellular matrix and cardiac dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Metalloproteinases and plasminogen activators in vessel remodeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Matrix Metalloproteinase Expressions in Arteriosclerotic Aneurysmal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Hypercholesterolemia increases endothelial superoxide anion production

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Clinical implications of matrix metalloproteinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Effects of statin on plaque stability and thrombogenicity in hypercholesterolemic patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high-resolution, noninvasive magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Indomethacin inhibits expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of cyclooxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Plaque-Stabilizing Effect of Pitavastatin in Watanabe Heritable Hyperlipidemic(WHHL) Rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Peripheral blood levels of matrix metalloproteases-2 and -9 are elevated in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Differential effects of doxycycline, a broad-spectrum matrix metalloproteinase inhibitor, on angiotensin II-induced atherosclerosis and abdominal aortic aneurysms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Complex roles of tissue inhibitors of metalloproteinases in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Matrix metalloproteinases: biologic activity and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Marimastat inhibits elastin degradation and matrix metalloproteinase 2 activity in a model of aneurysm disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

Prospective, Randomized, Double-Blind Trial Investigating the Effect of Doxycycline on Matrix Metalloproteinase Expression Within Atherosclerotic Carotid Plaques

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.024

21 January 2018

Identifiers

DOI

10.1515/CCLM.2004.024

1 reference

10 August 2017

1 reference